Envafolimab - Alphamab Oncology/Ascletis/3D Medicine
Alternative Names: ASC 22; ENWEIDA; KN-035Latest Information Update: 15 Jul 2024
At a glance
- Originator Alphamab Oncology
- Developer 3D Medicines; Alphamab Oncology; Ascletis; Chipscreen Biosciences; Jiangsu Simcere Pharmaceutical; Sun Yat-Sen University; The First Affiliated Hospital of Xiamen University; TRACON Pharmaceuticals
- Class Antibodies; Antineoplastics; Antiretrovirals; Antivirals; Immunotherapies; Recombinant fusion proteins; Single-domain antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Solid tumours
- Phase III Biliary cancer; Non-small cell lung cancer
- Phase II Endometrial cancer; Gastrointestinal cancer; Hepatitis B; HER2 positive breast cancer; HIV infections; Liver cancer; Malignant fibrous histiocytoma; Renal cell carcinoma; Soft tissue sarcoma
Most Recent Events
- 01 Jul 2024 Efficacy data from a phase II ENVASARC trial for Malignant fibrous histiocytoma and Soft tissue sarcoma released by TRACON Pharmaceuticals
- 01 Jul 2024 TRACON Pharmaceuticals terminates a phase II ENVASARC trial in Malignant fibrous histiocytoma and Soft tissue sarcoma in USA
- 31 May 2024 Efficacy and adverse events data from a phase II trial in Endometrial cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology, 2024 (ASCO-2024)